Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape.
Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predisposing factors are misfolding of abnormal protein called the light chain and its subsequent deposition in the body. It may also occur as a result of dialysis. Symptoms include fatigue, chest pain, swelling and breathing problems. Amyloidosis can be managed by transplant and, medication such as diuretics and chemotherapy drugs.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Amyloidosis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Amyloidosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Amyloidosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 1, 7, 11, 9, 1, 14 and 12 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase 0, Preclinical and Discovery stages comprises 1, 1, 1, 1 and 1 molecules, respectively.
Amyloidosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Amyloidosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Amyloidosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Amyloidosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Amyloidosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Amyloidosis (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Amyloidosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Amyloidosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Amyloidosis - Overview
Amyloidosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Amyloidosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Amyloidosis - Companies Involved in Therapeutics Development
Amyloidosis - Drug Profiles
Amyloidosis - Dormant Projects
Amyloidosis - Discontinued Products
Amyloidosis - Product Development Milestones
Featured News & Press Releases
Feb 17, 2022: Intellia Therapeutics announces two upcoming investor events in February 2022
Jan 24, 2022: Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
Jan 21, 2022: Alnylam presents positive 18-Month results from HELIOS-A phase 3 study of investigational Vutrisiran in patients with hATTR amyloidosis with polyneuropathy
Jan 14, 2022: Alnylam to present full 18-month results from the HELIOS-A phase 3 study of vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
Dec 27, 2021: BridgeBio Pharma reports month 12 topline results from phase 3 ATTRibute-CM study
Dec 27, 2021: BridgeBio Pharma reports month 12 topline results from phase 3 ATTRibute-CM study
Dec 13, 2021: Attralus presents positive new data at 2021 American Society of Hematology Annual Meeting
Nov 22, 2021: Intellia Therapeutics announces expansion of ongoing phase 1 study of NTLA-2001 to include adults with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)
Nov 22, 2021: Intellia Therapeutics announces expansion of ongoing phase 1 study of NTLA-2001 to include adults with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)
Nov 04, 2021: Attralus to present new data at 2021 American Society of Hematology Annual Meeting
Oct 27, 2021: Alnylam reports positive topline 18-month results from HELIOS-A phase 3 study of Vutrisiran in patients with hATTR amyloidosis with polyneuropathy
Oct 27, 2021: Alnylam reports positive topline 18-month results from HELIOS-A phase 3 study of Vutrisiran in patients with hATTR amyloidosis with polyneuropathy
Oct 21, 2021: Intellia Therapeutics receives U.S. FDA Orphan Drug Designation for NTLA-2001, an investigational CRISPR therapy for the treatment of transthyretin (ATTR) amyloidosis
Oct 11, 2021: Tegsedi receives innovative drug category pricing in Brazil
Sep 13, 2021: Alnylam submits marketing authorization application to the European Medicines Agency for investigational vutrisiran for the treatment of hereditary ATTR amyloidosis with polyneuropathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Amyloidosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Amyloidosis - Pipeline by 3SBio Inc, 2022
Amyloidosis - Pipeline by AbbVie Inc, 2022
Amyloidosis - Pipeline by ADRx Inc, 2022
Amyloidosis - Pipeline by Akcea Therapeutics Inc, 2022
Amyloidosis - Pipeline by Alexion Pharmaceuticals Inc, 2022
Amyloidosis - Pipeline by Alnylam Pharmaceuticals Inc, 2022
Amyloidosis - Pipeline by Amgen Inc, 2022
Amyloidosis - Pipeline by Amyl Therapeutics, 2022
Amyloidosis - Pipeline by Attralus Inc, 2022
Amyloidosis - Pipeline by Autotac Bio Inc, 2022
Amyloidosis - Pipeline by Auven Therapeutics Development Switzerland Sarl, 2022
Amyloidosis - Pipeline by BridgeBio Pharma Inc, 2022
Amyloidosis - Pipeline by Bristol-Myers Squibb Co, 2022
Amyloidosis - Pipeline by Brooklyn ImmunoTherapeutics Inc, 2022
Amyloidosis - Pipeline by BSIM Therapeutics SA, 2022
Amyloidosis - Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Amyloidosis - Pipeline by Corino Therapeutics Inc, 2022
Amyloidosis - Pipeline by Covalent Bioscience Inc, 2022
Amyloidosis - Pipeline by Dren Bio Inc, 2022
Amyloidosis - Pipeline by EUSA Pharma (UK) Ltd, 2022
Amyloidosis - Pipeline by GlaxoSmithKline Plc, 2022
Amyloidosis - Pipeline by Guangdong Yinzhu Pharmaceutical Technology Co Ltd, 2022
Amyloidosis - Pipeline by HaemaLogix Pty Ltd, 2022
Amyloidosis - Pipeline by IMMvention Therapeutix Inc, 2022
Amyloidosis - Pipeline by Johnson & Johnson, 2022
Amyloidosis - Pipeline by Karyopharm Therapeutics Inc, 2022
Amyloidosis - Pipeline by Mabpharm Ltd, 2022
Amyloidosis - Pipeline by Millennium Pharmaceuticals Inc, 2022
Amyloidosis - Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Amyloidosis - Pipeline by Novo Nordisk AS, 2022
Amyloidosis - Pipeline by Precision Biosciences Inc, 2022
Amyloidosis - Pipeline by Proclara Biosciences Inc, 2022
Amyloidosis - Pipeline by Prothena Corp Plc, 2022
Amyloidosis - Pipeline by R-Pharm, 2022
Amyloidosis - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Amyloidosis - Pipeline by ResQ Biotech, 2022
Amyloidosis - Pipeline by Sanofi, 2022
Amyloidosis - Pipeline by Shanghai YaKe Biotechnology Co Ltd, 2022
Amyloidosis - Pipeline by SOLA Biosciences LLC, 2022
Amyloidosis - Pipeline by Sorrento Therapeutics Inc, 2022
Amyloidosis - Pipeline by Spectrum Pharmaceuticals Inc, 2022
Amyloidosis - Pipeline by Telix Pharmaceuticals Ltd, 2022
Amyloidosis - Pipeline by Vera Therapeutics Inc, 2022
Amyloidosis - Pipeline by Zentalis Pharmaceuticals Inc, 2022
Amyloidosis - Dormant Projects, 2022
Amyloidosis - Dormant Projects, 2022 (Contd..1)
Amyloidosis - Discontinued Products, 2022
List of Figures
Number of Products under Development for Amyloidosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
